Vtv Therapeutics Stock Performance
| VTVT Stock | USD 24.44 0.40 1.66% |
VTv Therapeutics holds a performance score of 13 on a scale of zero to a hundred. The entity has a beta of 1.16, which indicates a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, VTv Therapeutics will likely underperform. Use vTv Therapeutics treynor ratio, expected short fall, as well as the relationship between the Expected Short fall and day median price , to analyze future returns on vTv Therapeutics.
Risk-Adjusted Performance
13 of 100
Weak | Strong |
Good
Compared to the overall equity markets, risk-adjusted returns on investments in vTv Therapeutics are ranked lower than 13 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak basic indicators, VTv Therapeutics unveiled solid returns over the last few months and may actually be approaching a breakup point. ...more
Actual Historical Performance (%)
One Day Return 2.99 | Five Day Return 3.9 | Year To Date Return 130.88 | Ten Year Return (94.28) | All Time Return (94.28) |
Last Split Factor 1:40 | Last Split Date 2023-11-21 |
1 | Discretionary transaction by Akkaraju Srinivas of tradable shares of VTv Therapeutics subject to Rule 16b-3 | 02/23/2024 |
2 | Acquisition by Akkaraju Srinivas of 224732 shares of VTv Therapeutics at 11.81 subject to Rule 16b-3 | 02/27/2024 |
3 | Why Is Diabetes Focused vTv Therapeutics Stock Trading Higher Today | 02/28/2024 |
4 | VTv Therapeutics exotic insider transaction detected | 02/29/2024 |
5 | vTv Therapeutics starts phase 3 trial for diabetes drug | 03/04/2024 |
6 | Disposition of 4776 shares by Baker Bros. Advisors Lp of VTv Therapeutics subject to Rule 16b-3 | 03/05/2024 |
7 | How To Trade - Stock Traders Daily.com | 03/07/2024 |
8 | Acquisition by Isaacsohn Jonathan of 50000 shares of VTv Therapeutics subject to Rule 16b-3 | 03/08/2024 |
9 | VTv Therapeutics Q4 Earnings Snapshot | 03/13/2024 |
10 | vTv Therapeutics Appoints Anne Phillips, Reshuffles Board Committees - TipRanks.com - TipRanks | 03/15/2024 |
11 | Insider Trading | 03/18/2024 |
12 | Should You Buy vTv Therapeutics Inc Stock on Wednesday - InvestorsObserver | 03/20/2024 |
13 | vTv Therapeutics files 250M mixed securities shelf | 04/10/2024 |
14 | Acquisition by John Fry of 205 shares of VTv Therapeutics at 0.8262 subject to Rule 16b-3 | 04/12/2024 |
15 | vTv Therapeutics Stock Price Passes Above Fifty Day Moving Average of 18.21 - Defense World | 04/19/2024 |
| Begin Period Cash Flow | 12.1 M |
VTv |
VTv Therapeutics Relative Risk vs. Return Landscape
If you would invest 859.00 in vTv Therapeutics on January 24, 2024 and sell it today you would earn a total of 1,585 from holding vTv Therapeutics or generate 184.52% return on investment over 90 days. vTv Therapeutics is currently generating 2.3873% in daily expected returns and assumes 13.8931% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than VTv, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
VTv Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for VTv Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as vTv Therapeutics, and traders can use it to determine the average amount a VTv Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.1718
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | VTVT | |||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 13.89 actual daily | 96 96% of assets are less volatile |
Expected Return
| 2.39 actual daily | 47 53% of assets have higher returns |
Risk-Adjusted Return
| 0.17 actual daily | 13 87% of assets perform better |
Based on monthly moving average VTv Therapeutics is performing at about 13% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of VTv Therapeutics by adding it to a well-diversified portfolio.
VTv Therapeutics Fundamentals Growth
VTv Stock prices reflect investors' perceptions of the future prospects and financial health of VTv Therapeutics, and VTv Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on VTv Stock performance.
| Return On Equity | -49.78 | ||||
| Return On Asset | -0.72 | ||||
| Current Valuation | 56.6 M | ||||
| Shares Outstanding | 2.43 M | ||||
| Price To Earning | (4.19) X | ||||
| Price To Sales | 3,631 X | ||||
| Revenue | 9 K | ||||
| Gross Profit | (9.93 M) | ||||
| EBITDA | (25.41 M) | ||||
| Net Income | (20.25 M) | ||||
| Cash And Equivalents | 17.95 M | ||||
| Cash Per Share | 0.22 X | ||||
| Total Debt | 529 K | ||||
| Debt To Equity | 0.08 % | ||||
| Current Ratio | 3.12 X | ||||
| Book Value Per Share | (11.84) X | ||||
| Cash Flow From Operations | (18.52 M) | ||||
| Earnings Per Share | (9.71) X | ||||
| Market Capitalization | 59.45 M | ||||
| Total Asset | 11.02 M | ||||
| Retained Earnings | (281.04 M) | ||||
| Working Capital | 38 K | ||||
| Current Asset | 52.12 M | ||||
| Current Liabilities | 10.58 M | ||||
About VTv Therapeutics Performance
To evaluate vTv Therapeutics Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when VTv Therapeutics generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare VTv Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand vTv Therapeutics market performance in a much more refined way. The Macroaxis performance score is an integer between 0 and 100 that represents VTv's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 53.56 | 97.59 | |
| Return On Tangible Assets | (1.84) | (1.93) | |
| Return On Capital Employed | (63.91) | (60.72) | |
| Return On Assets | (1.84) | (1.93) | |
| Return On Equity | 0.82 | 0.47 |
Things to note about vTv Therapeutics performance evaluation
Checking the ongoing alerts about VTv Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for vTv Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| vTv Therapeutics is way too risky over 90 days horizon | |
| vTv Therapeutics appears to be risky and price may revert if volatility continues | |
| The company reported the previous year's revenue of 9 K. Net Loss for the year was (20.25 M) with loss before overhead, payroll, taxes, and interest of (9.93 M). | |
| vTv Therapeutics currently holds about 17.95 M in cash with (18.52 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.22. | |
| vTv Therapeutics has a frail financial position based on the latest SEC disclosures | |
| Roughly 55.0% of the company outstanding shares are owned by insiders | |
| Latest headline from news.google.com: vTv Therapeutics Stock Price Passes Above Fifty Day Moving Average of 18.21 - Defense World |
- Analyzing VTv Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether VTv Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining VTv Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating VTv Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of VTv Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of VTv Therapeutics' stock. These opinions can provide insight into VTv Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in vTv Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in real. For more information on how to buy VTv Stock please use our How to Invest in VTv Therapeutics guide.You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Complementary Tools for VTv Stock analysis
When running VTv Therapeutics' price analysis, check to measure VTv Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy VTv Therapeutics is operating at the current time. Most of VTv Therapeutics' value examination focuses on studying past and present price action to predict the probability of VTv Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move VTv Therapeutics' price. Additionally, you may evaluate how the addition of VTv Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Stocks Directory Find actively traded stocks across global markets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data |
Is VTv Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of VTv Therapeutics. If investors know VTv will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about VTv Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (9.71) | Revenue Per Share 0.004 | Return On Assets (0.72) | Return On Equity (49.78) |
The market value of vTv Therapeutics is measured differently than its book value, which is the value of VTv that is recorded on the company's balance sheet. Investors also form their own opinion of VTv Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is VTv Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because VTv Therapeutics' market value can be influenced by many factors that don't directly affect VTv Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between VTv Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if VTv Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, VTv Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.